Skip to main content
Premium Trial:

Request an Annual Quote

Sirna to Supply GSK with RNAi-based Therapeutics for Respiratory Disease

NEW YORK, May 4 (GenomeWeb News) - Sirna Therapeutics said today that it will provide GlaxoSmithKline with siRNA therapeutics against asthma, respiratory syncytial virus, chronic obstructive pulmonary disease, and allergic rhinitis as part of its ongoing collaboration with the pharmaceutical company.

 

Sirna will provide GSK with optimized siRNAs against targets for these diseases and GSK is responsible for further preclinical and clinical development of compounds that emerge from the collaboration.

 

Sirna did not disclose financial details of the agreement.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.